BioNTech’s 2026 AGM approved an expansion of the Supervisory Board. Two new members with backgrounds in oncology, commercialization, and clinical development were appointed. The board change aligns ...
Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and ...
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam ...
The German biotech is struggling to redefine itself post-Covid, and an oncology push is part of the solution.
FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine ...
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, ...
Fintel on MSN
Bernstein initiates coverage of BioNTech SE - depositary receipt (BNTX) with market perform recommendation
Fintel reports that on May 22, 2026, Bernstein initiated coverage of BioNTech SE - Depositary Receipt (NasdaqGS:BNTX) with a ...
BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...
When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some financial analysts said the buyout amounted to an out-of-court settlement of ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases.
BioNTech SE (NASDAQ: BNTX) and Bristol Myers Squibb & Co. (NYSE: BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy ...
The company said it would exit operations at some manufacturing plants in Germany and Singapore, and that as many as 1,860 roles will be affected.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results